PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Taysha Gene Therapies, Inc. (TSHA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US8776191061

CUSIP

877619106

Sector

Healthcare

IPO Date

Sep 24, 2020

Highlights

Market Cap

$411.94M

EPS (TTM)

$0.63

PE Ratio

3.19

Total Revenue (TTM)

$9.92M

Gross Profit (TTM)

$8.92M

EBITDA (TTM)

-$85.64M

Year Range

$1.19 - $4.32

Target Price

$6.59

Short %

11.36%

Short Ratio

10.60

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
TSHA vs. OPEN TSHA vs. OLMA TSHA vs. PFIE
Popular comparisons:
TSHA vs. OPEN TSHA vs. OLMA TSHA vs. PFIE

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Taysha Gene Therapies, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%JuneJulyAugustSeptemberOctoberNovember
-23.76%
12.53%
TSHA (Taysha Gene Therapies, Inc.)
Benchmark (^GSPC)

Returns By Period

Taysha Gene Therapies, Inc. had a return of 39.55% year-to-date (YTD) and 34.24% in the last 12 months.


TSHA

YTD

39.55%

1M

25.38%

6M

-23.77%

1Y

34.24%

5Y (annualized)

N/A

10Y (annualized)

N/A

^GSPC (Benchmark)

YTD

25.15%

1M

2.74%

6M

12.53%

1Y

30.93%

5Y (annualized)

13.79%

10Y (annualized)

11.18%

Monthly Returns

The table below presents the monthly returns of TSHA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-14.12%107.89%-9.18%-15.33%41.15%-34.69%-1.34%1.36%-10.27%-15.92%39.55%
2023-27.43%-38.41%-20.99%-2.88%-9.81%-5.44%1.82%375.48%-1.25%-25.95%-24.79%0.57%-21.68%
2022-31.76%-19.87%2.35%-43.87%-30.33%45.88%9.41%-22.36%-38.92%-10.88%28.49%2.26%-80.60%
2021-2.03%-1.58%-20.67%27.14%-12.82%-5.78%-18.44%14.98%-6.34%-16.00%-17.01%-10.25%-56.10%
2020-6.90%-7.14%8.75%17.33%10.31%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of TSHA is 57, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of TSHA is 5757
Combined Rank
The Sharpe Ratio Rank of TSHA is 5353
Sharpe Ratio Rank
The Sortino Ratio Rank of TSHA is 6262
Sortino Ratio Rank
The Omega Ratio Rank of TSHA is 5959
Omega Ratio Rank
The Calmar Ratio Rank of TSHA is 5858
Calmar Ratio Rank
The Martin Ratio Rank of TSHA is 5353
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Taysha Gene Therapies, Inc. (TSHA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for TSHA, currently valued at 0.31, compared to the broader market-4.00-2.000.002.004.000.312.53
The chart of Sortino ratio for TSHA, currently valued at 1.34, compared to the broader market-4.00-2.000.002.004.001.343.39
The chart of Omega ratio for TSHA, currently valued at 1.16, compared to the broader market0.501.001.502.001.161.47
The chart of Calmar ratio for TSHA, currently valued at 0.36, compared to the broader market0.002.004.006.000.363.65
The chart of Martin ratio for TSHA, currently valued at 0.98, compared to the broader market0.0010.0020.0030.000.9816.21
TSHA
^GSPC

The current Taysha Gene Therapies, Inc. Sharpe ratio is 0.31. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Taysha Gene Therapies, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio0.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
0.31
2.53
TSHA (Taysha Gene Therapies, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Taysha Gene Therapies, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-92.22%
-0.53%
TSHA (Taysha Gene Therapies, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Taysha Gene Therapies, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Taysha Gene Therapies, Inc. was 98.14%, occurring on Jun 28, 2023. The portfolio has not yet recovered.

The current Taysha Gene Therapies, Inc. drawdown is 92.22%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.14%Jan 21, 2021613Jun 28, 2023
-21.78%Sep 28, 202050Dec 7, 202012Dec 23, 202062
-10.74%Dec 24, 20208Jan 6, 20216Jan 14, 202114

Volatility

Volatility Chart

The current Taysha Gene Therapies, Inc. volatility is 52.34%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%JuneJulyAugustSeptemberOctoberNovember
52.34%
3.97%
TSHA (Taysha Gene Therapies, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Taysha Gene Therapies, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Taysha Gene Therapies, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items